Additionally, the use of aromatase inhibitors in postmenopausal breast cancer patients was shown to be effective, as these medications block the conversion of androgens into estrogens by aromatase in adipose tissue, which is the main source of estrogen in a postmenopausal patient [4,22]. This evidence concerns the gene CYP19A1 and breast carcinoma.